Integrity Laboratories

Executive Summary

Integrity Laboratories is a Nashville-based clinical diagnostics company established in 2013 that specializes in high-complexity laboratory testing across infectious disease diagnostics, toxicology, and pharmacogenomics. The company operates genomIQ, an applied science incubator focused on developing and commercializing novel diagnostic technologies. By leveraging advanced testing methodologies, Integrity Laboratories aims to provide accurate and timely results to support clinical decision-making, particularly in areas with high unmet needs such as infectious disease management and personalized medicine through pharmacogenomic testing. Despite being a private entity with limited public financial disclosure, the company has established a foothold in the competitive diagnostics landscape and continues to expand its test menu and technological capabilities through internal development and its incubator arm. Looking ahead, Integrity Laboratories is positioned to benefit from growing demand for rapid, precise diagnostics in infectious disease and the increasing adoption of pharmacogenomics in clinical practice. The company's incubator may yield new proprietary tests or partnerships that enhance its market position. However, as a private company, its progress is less transparent, and its ability to scale depends on securing funding or strategic collaborations. Overall, Integrity Laboratories represents a niche player in the diagnostics sector with potential for growth if it can successfully commercialize innovations from its incubator and capture market share in key testing areas.

Upcoming Catalysts (preview)

• Q3 2026Launch of a novel infectious disease diagnostic panel through genomIQ60% success
• Q4 2026Securing a strategic partnership or distribution agreement with a larger diagnostic company50% success
• Q1 2027Obtaining FDA 510(k) clearance for a pharmacogenomic test40% success